Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,715.19 +188.09 (+0.27%) CMC Crypto 200
1,514.71 +26.17 (+1.76%)
Standard BioTools Inc. (LAB)
After hours:
| Previous close | 2.5800 |
| Open | 2.5800 |
| Bid | 2.5600 x 900 |
| Ask | 2.5900 x 900 |
| Day's range | 2.5300 - 2.5950 |
| 52-week range | 1.5700 - 3.1600 |
| Volume | |
| Avg. volume | 2,532,409 |
| Market cap | 977.461M |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.58 |
GlobeNewswireStandard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20, 2024, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan). The equity award consisted of an award of 207,832 restricted stock units (RSUs) as a material inducement to a new empl
Insider MonkeyStandard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript
Standard BioTools Inc. (NASDAQ:LAB) Q1 2024 Earnings Call Transcript May 11, 2024 Standard BioTools Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Standard BioTools Inc. First Quarter 2024 Earnings Conference Call. All participants […]
- GlobeNewswire
Standard BioTools Reports First Quarter 2024 Financial Results
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, res
